OrbiMed Genesis Master Fund, LP plan to sell securities of Keros Therapeutics, Inc. under Form 144

OrbiMed Genesis Master Fund, LP filed Form 144 to notify SEC of plan to sell 45057 units of Keros Therapeutics, Inc. securities around 2026-03-31, with aggregate market value of $497,429.28. The total outstanding units is 19717533.0. The amount planned to be sold represents 0.23% of total outstanding units;